SCHEMBL5566618

SCHEMBL5566618

COc1ccc(-c2cc(Oc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)n[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 0.61
▸ FLT4 P35916 14/20 0.61
▸ TEK Q02763 7/20 0.61
▸ AURKB Q96GD4 7/20 0.61
▸ AURKA O14965 6/20 0.61
▸ PDGFRB P09619 6/20 0.61
▸ EGFR P00533 7/20 0.52
▸ ERBB2 P04626 4/20 0.51
▸ FLT1 P17948 9/20 0.51
▸ FGFR1 P11362 3/20 0.51
▸ SRC P12931 2/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ GAK O14976 1/20 0.51
▸ EPHB6 O15197 1/20 0.51
▸ RIPK2 O43353 1/20 0.51
▸ ERN1 O75460 1/20 0.51
▸ STK10 O94804 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ CHEK2 O96017 1/20 0.51
▸ ABL1 P00519 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565932 0.92 KDR (0.60) KDRFLT4TEKAURKBAURKA
SCHEMBL5561051 0.92 FLT4 (0.52) KDRFLT4TEKAURKBAURKA
SCHEMBL7885709 0.87 KDR (0.53) KDRFLT4TEKAURKBAURKA
SCHEMBL5566455 0.86 EGFR (0.53) KDREGFRSRCKIT
SCHEMBL5565927 0.86 KDM1A (0.54) KDRFLT4TEKAURKBAURKA
SCHEMBL5565947 0.85 KDR (0.55) KDRFLT4TEKAURKBAURKA
SCHEMBL5561123 0.85 EGFR (0.56) KDRFLT4EGFRERBB2FLT1
SCHEMBL5565918 0.85 SRC (0.57) KDRFLT4TEKAURKBAURKA
SCHEMBL5561384 0.85 KDM1A (0.54) KDRFLT4TEKAURKBAURKA
SCHEMBL6443640 0.85 KDR (0.45) KDRFLT4TEKAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP claimed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed
Send feedback